News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asuragen, Inc. Release: Results of a Multi-Center Study Show MicroRNA-Based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology


11/4/2011 9:03:22 AM

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that data from a multi-center study evaluating its microRNA-based test, miRInformâ„¢ Pancreas, for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) in fine needle aspirates, was presented as a Poster of Distinction at the American Pancreatic Association (APA) Annual Meeting being held November 2-5, 2011 in Chicago.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES